EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma

Jennifer A Lenz, Brandon Peng, Charles-Antoine Assenmacher, Austin King, Paul J Zhang, Robert G Maki, M Andres Blanco, Enrico Radaelli, Matthew J Atherton

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03908-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Jennifer A Lenz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Histiocytic Sarcoma, Tumor Microenvironment. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Penn Vet Companion Animal Research Fund, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histiocytic sarcoma (HS) is a rare yet lethal malignancy with no established standard of care therapies. A lack of pre-clinical models limits our understanding of HS pathogenesis and identification of therapeutic targets. Canine HS shares multiple clinical and genetic similarities with human HS, supporting its use as a unique translational model. Prior studies have investigated the immunogenicity of HS. Although increased tumor infiltrating lymphocyte (TIL) density is associated with favorable outcomes in canine HS, virtually all canine patients eventually succumb to progressive disease consistent with ultimate failure of anti-tumor immunity. To investigate potential regulators of the immune tumor microenvironment (TME), we undertook a comparative transcriptional approach of three long-lived cases of canine pulmonary HS with heavy T cell infiltrate and three short-lived cases of splenic HS that lacked significant T cell inflammation and compared these data to corresponding grossly normal tissues from dogs undergoing necropsy. This comparison identified PDCD1, encoding the immune checkpoint PD-1, and SPP1, encoding the secreted pro-tumorigenic protein osteopontin, as positive differentially expressed genes (DEGs) in canine HS. TXNIP, encoding the tumor suppressor TXNIP, was the most significant negative DEG. Comparative transcriptomic studies revealed conservation of enriched (including SPP1 ) and depleted (including TXNIP ) DEGs between canine and human HS patients. Immunohistochemistry demonstrated osteopontin in the TMEs of canine and human HS. Collectively, we uncover PD-1, osteopontin, and TXNIP as putative actionable targets in HS and further establish canine HS as a preclinical platform to screen novel immunotherapeutic approaches for this deadly disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histiocytic SarcomaTumor MicroenvironmentAnimalsDogsGene Expression ProfilingDog DiseasesHumansFemaleGene Expression Regulation, NeoplasticLymphocytes, Tumor-InfiltratingMaleProgrammed Cell Death 1 ReceptorTranscriptome

Stichwörter der Autor:innen

Histiocytic sarcomaOsteopontinPD-1TXNIP

Substanzen

Programmed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. mattath@upenn.edu.

Förderung

  • NCI NIH HHS
  • Penn Vet Companion Animal Research Fund
  • National Cancer Institute

Zitieren

APA

Lenz, J. A., Peng, B., Assenmacher, C. A., King, A., Zhang, P. J., Maki, R. G., Blanco, M. A., Radaelli, E., & Atherton, M. J. (2025). Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03908-x

Vancouver

Lenz JA, Peng B, Assenmacher CA, King A, Zhang PJ, Maki RG, et al. Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03908-x

BibTeX
@article{Lenz2025,
  author = {Lenz, Jennifer A and Peng, Brandon and Assenmacher, Charles-Antoine and King, Austin and Zhang, Paul J and Maki, Robert G and Blanco, M Andres and Radaelli, Enrico and Atherton, Matthew J},
  title = {Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03908-x}
}
Kostenlos starten →